ライフサイエンスコーパス: positive symptom

1 d cingulate gyri correlated with severity of positive symptoms.

2 in negative and depressive symptoms but not positive symptoms.

3 The majority targeted treatment resistant positive symptoms.

4 variability in symptom severity or negative/positive symptoms.

5 nse criteria required sustained remission of positive symptoms.

6 no difference between groups in the rate of positive symptoms.

7 impairment) and in those with predominantly positive symptoms.

8 ative symptoms from those with predominantly positive symptoms.

9 putamen correlated with less improvement in positive symptoms.

10 ognitive disorganization but not negative or positive symptoms.

11 y of life, symptom severity, or remission of positive symptoms.

12 , symptom severity, and time to remission of positive symptoms.

13 apine without glycine had a 35% reduction in positive symptoms.

14 ributable to the Scale for the Assessment of Positive Symptoms.

15 ymptoms and temporal lobe abnormalities with positive symptoms.

16 ted with transient emergence or worsening of positive symptoms.

17 chronic hospital patients did not differ on positive symptoms.

18 pine was superior to haloperidol in treating positive symptoms.

19 the putamen were associated with more severe positive symptoms.

20 ) than in normal subjects and are related to positive symptoms.

21 d with greater severity of both negative and positive symptoms.

22 pontaneous SCR frequency was associated with positive symptoms.

23 Symptoms and the Scale for the Assessment of Positive Symptoms.

24 showing quetiapine's consistency in reducing positive symptoms.

25 s memory responses were positively linked to positive symptoms.

26 ive rehabilitation, and coping with residual positive symptoms.

27 ng Scale, and the Scale of the Assessment of Positive Symptoms.

28 This deficit correlated with positive symptoms.

29 ed with opposite correlations between RD and positive symptoms.

30 The alpha activity correlated with positive symptoms.

31 e to PFC-dependent correlates of negative or positive symptoms.

32 ot induce clinically significant increase in positive symptoms.

33 ith age, and NAAc correlated negatively with positive symptoms.

34 ed response in patients who only experienced positive symptoms.

35 hippocampal activity that is correlated with positive symptoms.

36 spindles correlated with greater severity of positive symptoms.

37 l striatum was correlated with the degree of positive symptoms.

38 induced cognitive deficits and negative and positive symptoms.

39 e-induced cognitive deficits or negative and positive symptoms.

40 lusion correlated with increased severity of positive symptoms.

41 e changes were associated with the degree of positive symptoms.

42 d patients showed significant improvement in positive symptoms (52% and 44% reductions from baseline,

43 t of which have been shown to correlate with positive symptoms: aberrant learning for neutral cues (a

44 rome to determine which patients receive the positive symptom advantage of clozapine and the extent o

45 Among patients, change in positive symptoms after amphetamine was significantly as

46 Negative and positive symptoms also worsened (Cohen's d values, 0.45-

47 of medication nonadherence on the return of positive symptoms among recent-onset schizophrenia patie

48 CGI severity and improvement ratings, PANSS positive symptom and general psychopathology subscales,

49 ion, despite an inverse relationship between positive symptoms and activation.

50 tive and Negative Syndrome Scale factors for positive symptoms and anxiety/depression were greater wi

51 s studied, ketamine and amphetamine produced positive symptoms and euphoria.

52 ces of dopaminergic mechanisms as a cause of positive symptoms and executive deficits.

53 efits of the program included a reduction in positive symptoms and in symptom exacerbations and an in

54 The severity of attenuated positive symptoms and overall functioning were assessed.

55 Clozapine was superior to risperidone for positive symptoms and parkinsonian side effects, but the

56 s and failure to respond, as well as between positive symptoms and production of erroneous responses.

57 ous phasic dopamine release helps to explain positive symptoms and provides a unified explanation for

58 ting scales (the Scale for the Assessment of Positive Symptoms and the alogia subscale of the Scale f

59 onal outcomes were not entirely dependent on positive symptoms and the development of psychosis, furt

60 ared to both the subjects with predominantly positive symptoms and the normal subjects.

61 ssessed with the Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Ne

62 ere rated on the Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Ne

63 ssessed with the Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Ne

64 ssessed with the Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Ne

65 ia significantly correlated with severity of positive symptoms and thought disorder and with impairme

66 son subjects were evaluated for negative and positive symptoms and underwent comprehensive neuropsych

67 namely enhanced MK-801 psychomotor response (positive symptoms) and decreased working memory (cogniti

68 Three symptom factors-negative symptoms, positive symptoms, and affective symptoms-were all signi

69 the medial temporal lobe was correlated with positive symptoms, and baseline [(11)C]flumazenil VT in

70 s revealed three factors: negative symptoms, positive symptoms, and disorganization.

71 nsolidation in schizophrenia, contributes to positive symptoms, and is a promising novel target for t

72 ing predominance of women, lower severity of positive symptoms, and lower average antipsychotic dose

73 able schizophrenia, predominant NSS, limited positive symptoms, and maintained on stable atypical ant

74 erms of total symptoms, overall functioning, positive symptoms, and quality of life.

75 ety, negative symptoms, overall functioning, positive symptoms, and social functioning).

76 Nursing home patients had the least severe positive symptoms, and the acutely ill and chronic hospi

77 ation of untreated psychosis, past drug use, positive symptoms, and violent behavior.

78 represented dimensions of mania, depression, positive symptoms, anxiety, negative symptoms and disorg

79 e rehabilitation and training in coping with positive symptoms appear to be promising interventions,

80 d in the illness, correlate with measures of positive symptoms, are consistent with models of disease

81 We conclude that tonic and paroxysmal positive symptoms as well as negative symptoms may be a

82 gh preceded by reflux (mainly distal), 56% a positive symptom association probability (SAP(C-R (2 min

83 ted temporal associations, with 48% having a positive symptom association probability (SAP(R-C)) for

84 Symptoms and the Scale for the Assessment of Positive Symptoms at 18 months after randomization.

85 greater improvement than control subjects on positive symptoms at all time points and on negative sym

86 al scores on the Scale for the Assessment of Positive Symptoms at baseline and at follow-up.

87 nly if they exhibited one or more attenuated positive symptoms at moderate to severe, but not psychot

88 Symptoms and the Scale for the Assessment of Positive Symptoms) at index hospitalization and quality

89 prediction model was developed and included positive symptoms, bizarre thinking, sleep disturbances,

90 therapy, clozapine has superior efficacy for positive symptoms but not negative symptoms and is assoc

91 depressive symptoms correlated with that of positive symptoms but not with age, gender, negative sym

92 oduce fairly robust clinical benefit against positive symptoms but typically have minimal therapeutic

93 ntipsychotic drugs (APDs) show efficacy with positive symptoms, but are limited in treating negative

94 ative symptoms at any time after control for positive symptoms, but its effects on positive symptoms

95 of haloperidol over olanzapine for improving positive symptoms, but the benefit was scale-dependent:

96 iated with the transient amphetamine-induced positive-symptom change, as observed in schizophrenia.

97 bles, with end point differences in the BPRS positive-symptom cluster score showing quetiapine's cons

98 condary efficacy variables included the BPRS positive-symptom cluster score, the Modified Scale for t

99 Severity of Illness item; and P = .003, BPRS positive-symptom cluster) differences were identified be

100 , despite an absence of depressive symptoms, positive symptoms, comorbid systemic illnesses, or medic

101 ssions' Severity of Illness Scale as well as positive symptoms compared with those receiving placebo.

102 significantly with risperidone response were positive symptoms, conceptual disorganization, akathisia

103 he diagnosis of FAPS is made on the basis of positive symptom criteria and a longstanding history of

104 ore homogeneous high-risk sample (attenuated positive symptom criteria only, age range of mid-teens t

105 elapse (dCC-NC=0.36 vs dDC-NC=0.02, p=0.04), positive symptoms (dCC-NC=0.15 vs dDC-NC=-0.30, p=0.05)

106 r schizophrenia with suboptimally controlled positive symptoms despite treatment with antipsychotics.

107 Symptoms and the Scale for the Assessment of Positive Symptoms divided into 3 domains: psychotic, neg

108 st that patients with minimal improvement in positive symptoms during the first week of treatment wit

109 ate connectivity pattern and the severity of positive symptoms evaluated with the Positive and Negati

110 t (i.e., mediated by differential effects on positive symptoms, extrapyramidal symptoms, or mood).

111 s the mean change from baseline in the PANSS Positive Symptom Factor Score (PSFS) at week 12, analyse

112 ngs revealed a negative symptom factor and a positive symptom factor.

113 hed expression and disordered relating), two positive symptom factors (bizarre delusions and auditory

114 (two consecutive ratings without significant positive symptoms) for rare allele carriers versus wild

115 than other interventions pooled in reducing positive symptoms (g=0.16).

116 ptoms (g=0.42) and supportive counseling for positive symptoms (g=0.23).

117 rs1036145 showed significant improvement in positive symptoms, general psychopathology, and thought

118 ither SNP, showed significant improvement in positive symptoms, general psychopathology, thought dist

119 ively; P = .01; between-group d = -0.66) and positive symptoms (hallucinations, delusions, disorganiz

120 minergic function, are effective at reducing positive symptoms (i.e. delusions and hallucinations), t

121 ring treatment, the mean score for prodromal positive symptoms improved more in the olanzapine group

122 Positive symptoms in all nonaffective psychoses probands

123 ed with poorer treatment outcome in terms of positive symptoms in both groups.

124 ments in functional outcome, motivation, and positive symptoms in low-functioning patients with signi

125 study examined the frequency of negative and positive symptoms in nonpsychotic patients with temporal

126 The significant correlations between positive symptoms in schizophrenia and diffusion and NAA

127 is effective in treating negative as well as positive symptoms in schizophrenia resistant to standard

128 Amphetamine significantly increased positive symptoms in subjects with SCH (19.5 +/- 5.3 vs.

129 ut statistically significant, improvement in positive symptoms in the active rTMS group (p = .047, ef

130 y in schizophrenia predicted the severity of positive symptoms in the disorder, such as hallucination

131 n, that aberrant salience (and the resulting positive symptoms) in schizophrenia may arise, at least

132 thological features manifest behaviorally as positive symptoms (including hallucinations, delusions a

133 he flawed agency judgments characteristic of positive symptoms, including auditory hallucinations and

134 dopamine receptor antagonism in ameliorating positive symptoms, including auditory hallucinations, in

135 ried forward analyses on the sum of selected positive symptom items of the Brief Psychiatric Rating S

136 ent-by-brain structure interactions for BPRS positive symptom items.

137 chizophrenia patients with both negative and positive symptoms (n = 11) and schizophrenia patients wi

138 1) and schizophrenia patients with primarily positive symptoms (n = 11).

139 tures that can be parsed into three domains: positive symptoms, negative symptoms, and cognitive defi

140 ss a complex symptomatology characterized by positive symptoms, negative symptoms, and cognitive impa

141 S share fundamental clinical features (i.e., positive symptoms, negative symptoms, functional deficit

142 ntipsychotic medication in the management of positive symptoms of acute schizophrenia as well as nega

143 ms were significantly more likely to exhibit positive symptoms of psychosis after 24 months.

144 )mania, and contextually misallocated in the positive symptoms of psychosis.

145 nt in social and communication function, and positive symptoms of restricted and repetitive behaviors

146 nt in all medications that effectively treat positive symptoms of schizophrenia (e.g., delusions and

147 nistered Dissociative States Scale (P<.001); positive symptoms of schizophrenia as assessed by the Br

148 ic drugs are widely thought to alleviate the positive symptoms of schizophrenia by antagonizing dopam

149 Positive symptoms of schizophrenia correlated negatively

150 When SAR218645 was tested in models of the positive symptoms of schizophrenia, it reduced head twit

151 f the former appears to track improvement of positive symptoms of schizophrenia, the latter have rece

152 therapy in the treatment of drug-refractory positive symptoms of schizophrenia.

153 , VNS reversed a behavioral correlate of the positive symptoms of schizophrenia.

154 a more general physiologic deficit underlies positive symptoms of schizophrenia.

155 Positive symptoms of speech dysfunction were classified

156 with predominantly negative or predominantly positive symptoms on the basis of their post-drug-washou

157 In general, improvement in positive symptoms over the time interval was associated

158 ed with an increase in the severity of total positive symptoms over time (r=-0.33; df=47; P=0.02), mo

159 han in HS (p<0.032), and was associated with positive symptoms (p<0.007), antipsychotic load (p<0.015

160 ody of evidence demonstrates that persistent positive symptoms, particularly delusions, can be improv

161 normalities than subjects with predominantly positive symptoms, particularly in frontal, temporal, an

162 sessed once per test day, while negative and positive symptoms, perceptual alterations, and a number

163 ol for positive symptoms, but its effects on positive symptoms persisted after control for negative s

164 roup was indirect (ie, partially mediated by positive symptoms) (probit coefficient [beta] = 0.12; P

165 Among patients with attenuated positive symptoms, processing speed was related to socia

166 a separate sibpair analysis using scores on positive-symptom (psychotic), negative-symptom (deficit)

167 Ketamine produced psychotic-like positive symptoms, reductions in working memory and sust

168 ols correlated specifically with more severe positive symptoms (rho = -0.77, P = .002).

169 on's disease-adapted scale for assessment of positive symptoms (SAPS-PD) in all patients who received

170 on Rating Scale, Scale for the Assessment of Positive Symptoms, Scale for the Assessment of Negative

171 With the positive symptom-scale scores, the marker D6S1960 produc

172 ief Psychiatric Rating Scale total score and positive symptom score, Scale for the Assessment of Nega

173 ically significant treatment effect on PANSS positive symptom scores (beta for change in raloxifene v

174 nsion were related to greater BPRS total and positive symptom scores and longer time hospitalized.

175 nction signal was positively correlated with positive symptom scores during deceptive repayments.

176 elation between VS activity and negative and positive symptom scores in patients.

177 Dyskinetic movement scores correlated with positive symptom scores.

178 The response in the amygdala correlated with positive symptom severity (r = .16, P = .01) but not wit

179 In comparison, positive symptom severity is less strongly correlated wi

180 onfirmed association to patient delusion and positive symptom severity.

181 P < .001), but no correlation was found with positive symptom severity.

182 regions where FA correlated positively with positive symptoms severity.

183 (P < .05); however, other patients with low positive symptoms showed no significant deficits.

184 mptoms (primary outcomes), overall symptoms, positive symptoms, side effects, exacerbation of psychos

185 Positive symptoms (SMD 0.45) improved more than negative

186 pears to have a significant association with positive symptoms, specifically delusions.

187 n difference: -0.24, 95% CI=-0.39 to -0.09), positive symptoms (standardized mean difference: -0.17,

188 augmented AMPH-induced peak changes in PANSS positive symptom subscale and both subjective and object

189 e to week 6 and week 12, mean BPRS total and positive symptom subscale scores were reduced significan

190 sessed by the Brief Psychiatric Rating Scale positive symptoms subscale (P<.001); negative symptoms a

191 aracteristic of schizophrenia and related to positive symptoms, such as auditory hallucinations.

192 Two positive symptoms (suspiciousness and delusions), howeve

193 longer hospital admissions, and more severe positive symptoms than for individuals who discontinue c

194 ption betel chewers had significantly milder positive symptoms than low-consumption chewers over 1 ye

195 antipsychotic efficacy and rodent models of positive symptoms through antagonism of DA-D2 receptors,

196 was predictive of good treatment response of positive symptoms to antipsychotic drugs.

197 pilepsy and the relationship of negative and positive symptoms to cognition, quantitative magnetic re

198 reductions from the fluphenazine baseline in positive symptoms, total symptoms, and depression.

199 predictive accuracy compared with attenuated positive symptoms used alone.

200 tive rehabilitation and coping with residual positive symptoms was also examined.

201 The severity of negative and positive symptoms was assessed, medications were monitor

202 as seen when the Scale for the Assessment of Positive Symptoms was used but not when the Positive and

203 The expected link of one with positive symptoms was verified, but the link of the othe

204 work for the EOS patients with predominantly positive symptom were highly similar to typically develo

205 lutamate and amphetamine-induced subclinical positive symptoms were detected.

206 antipsychotic efficacy and those that model positive symptoms were employed and we found that L-Gova

207 Negative but not positive symptoms were more prevalent in temporal lobe e

208 elations in a subgroup of patients with high positive symptoms were significantly reduced from age 14

209 1)H-MRSI) and rating scales for negative and positive symptoms were used to study 36 patients with sc

210 Among women who screened positive, symptoms were recorded in 43% of the charts, d

211 ent as a complex combination of negative and positive symptoms, which vary enormously from individual

212 associated with more hallucinations and more positive symptoms, while lower relative glucose metaboli

213 nt improvements in negative symptoms without positive symptom worsening.